

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

We claim:

**Claim 1. (Currently Amended)** ~~Process~~ A process for the preparation of a highly concentrated, liquid formulation comprising ~~at least one anti-EGFR monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), comprising ultrafiltrating a preparation comprising said Mab c225 or Mab h425, wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml and/or one of its variants and/or fragments by ultrafiltration.~~

**Claim 2. (Cancelled)**

**Claim 3. (Cancelled)**

**Claim 4. (Currently Amended)** ~~Process~~ The process according to Claim 1, characterised in that the highly concentrated, liquid formulation obtained has a content of an anti-EGFR antibody of wherein the concentration of said antibody in said highly concentrated, liquid formulation is 100 – 150 mg/ml.

**Claim 5. (Cancelled)**

**Claim 6. (Cancelled)**

**Claim 7. (Cancelled)**

**Claim 8. (Currently Amended)** ~~Highly~~ A highly concentrated, liquid formulation comprising ~~at least one anti-EGFR monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml and/or one of its variants and/or fragments.~~

**Claim 9. (Cancelled)**

**Claim 10. (Cancelled)**

**Claim 11. (Currently Amended)** ~~Highly~~ The highly concentrated, liquid formulation according to Claim 8, characterised in that the highly concentrated, liquid formulation obtained has a content

of an anti-EGFR antibody of wherein the concentration of said antibody is 100 – 150 mg/ml.

Claim 12. (Cancelled)

Claim 13. (Cancelled)

Claim 14. (Cancelled)

Claim 15. (Cancelled)

Claim 16. (Currently Amended) ~~Highly concentrated, liquid formulation according to Claim 8~~  
as A storage-stable medicament pharmaceutical preparation which comprises a highly concentrated, liquid formulation according to claim 7 and an acceptable excipient or adjuvant.

Claim 17. (Currently Amended) ~~Highly A highly concentrated, liquid formulation according to Claim 8; characterised in that it which optionally further comprises an excipient, adjuvant or an additional pharmaceutical active ingredient excipients and/or adjuvants and/or further pharmaceutical active ingredients.~~

Claim 18. (Withdrawn) Use of a highly concentrated, liquid formulation according to Claim 8 for the preparation of a medicament.

Claim 19. (Withdrawn, Currently Amended) ~~Use of a highly concentrated, liquid formulation according to Claim 8 for the preparation of a medicament A method for the treatment and/or prophylaxis of a tumor or tumor metastasis, comprising administering to a subject in need thereof, the highly concentrated, liquid formulation according to claim 8 tumours and/or tumour metastases.~~

Claim 20. (Withdrawn, Currently Amended) ~~Use The method according to Claim 19, where the tumour is selected from the group consisting of brain tumour, tumour of the urogenital tract, tumour of the lymphatic system, stomach tumour, laryngeal tumour, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma and breast carcinoma wherein the tumor is brain tumor, tumor of the urogenital tract, tumor of the lymphatic system, stomach tumor, laryngeal tumor, monocytic leukemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.~~

Claim 21. (New) A kit which comprises a highly concentrated, liquid formulation according to

claim 7 and an additional medicament active ingredient.

**Claim 22. (New)** A process for the preparation of a highly concentrated, liquid formulation comprising monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425) consisting essentially of ultrafiltrating a preparation comprising said Mab c225 or Mab h425, wherein the concentration of said antibody in said highly concentrated, liquid formulation thus prepared is 50 mg/ml to 180 mg/ml.

**Claim 23. (New)** A highly concentrated, liquid formulation consisting essentially of monoclonal antibody c225 (Mab c225) or monoclonal antibody h425 (Mab h425), wherein the concentration of said antibody in said highly concentrated, liquid formulation is 50 mg/ml to 180 mg/ml.

**Claim 24. (New)** The highly concentrated, liquid formulation according to Claim 23, wherein the concentration of said antibody is 100 – 150 mg/ml.